Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Chapter 2: Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis.

Kaur D, Guerin ME, Skovierová H, Brennan PJ, Jackson M.

Adv Appl Microbiol. 2009;69:23-78. doi: 10.1016/S0065-2164(09)69002-X. Review.

2.

Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets.

Jankute M, Grover S, Rana AK, Besra GS.

Future Microbiol. 2012 Jan;7(1):129-47. doi: 10.2217/fmb.11.123. Review.

PMID:
22191451
3.

Targeting the formation of the cell wall core of M. tuberculosis.

Barry CE, Crick DC, McNeil MR.

Infect Disord Drug Targets. 2007 Jun;7(2):182-202. Review.

4.

The cell envelope glycoconjugates of Mycobacterium tuberculosis.

Angala SK, Belardinelli JM, Huc-Claustre E, Wheat WH, Jackson M.

Crit Rev Biochem Mol Biol. 2014 Sep-Oct;49(5):361-99. doi: 10.3109/10409238.2014.925420. Epub 2014 Jun 10. Review.

5.

Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis.

Brennan PJ.

Tuberculosis (Edinb). 2003;83(1-3):91-7. Review.

PMID:
12758196
6.

Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.

Jackson M, McNeil MR, Brennan PJ.

Future Microbiol. 2013 Jul;8(7):855-75. doi: 10.2217/fmb.13.52. Review.

7.

The cell-wall core of Mycobacterium tuberculosis in the context of drug discovery.

Brennan PJ, Crick DC.

Curr Top Med Chem. 2007;7(5):475-88. Review.

PMID:
17346193
8.
9.
10.

An approach for the rational design of new antituberculosis agents.

Pasqualoto KF, Ferreira EI.

Curr Drug Targets. 2001 Dec;2(4):427-37. Review.

PMID:
11732641
11.

Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis.

Crick DC, Mahapatra S, Brennan PJ.

Glycobiology. 2001 Sep;11(9):107R-118R. Review.

12.

Mycobacteriophage Ms6 LysB specifically targets the outer membrane of Mycobacterium smegmatis.

Gil F, Grzegorzewicz AE, Catalão MJ, Vital J, McNeil MR, Pimentel M.

Microbiology. 2010 May;156(Pt 5):1497-504. doi: 10.1099/mic.0.032821-0. Epub 2010 Jan 21.

13.

Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development.

Bailo R, Bhatt A, Aínsa JA.

Biochem Pharmacol. 2015 Aug 1;96(3):159-67. doi: 10.1016/j.bcp.2015.05.001. Epub 2015 May 16. Review.

PMID:
25986884
14.

The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan.

Alderwick LJ, Harrison J, Lloyd GS, Birch HL.

Cold Spring Harb Perspect Med. 2015 Mar 27;5(8):a021113. doi: 10.1101/cshperspect.a021113. Review.

PMID:
25818664
15.

Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis.

Schroeder EK, de Souza N, Santos DS, Blanchard JS, Basso LA.

Curr Pharm Biotechnol. 2002 Sep;3(3):197-225. Review.

PMID:
12164478
16.

Structure, function and biogenesis of the mycobacterial cell wall.

Brennan PJ, Besra GS.

Biochem Soc Trans. 1997 Feb;25(1):188-94. No abstract available.

PMID:
9056869
17.
18.

Synthesis and biological aspects of mycolic acids: an important target against Mycobacterium tuberculosis.

de Souza MV, Ferreira Mde L, Pinheiro AC, Saraiva MF, de Almeida MV, Valle MS.

ScientificWorldJournal. 2008 Jul 31;8:720-51. doi: 10.1100/tsw.2008.99. Review.

19.

SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.

Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE 3rd, Boshoff HI.

Antimicrob Agents Chemother. 2012 Apr;56(4):1797-809. doi: 10.1128/AAC.05708-11. Epub 2012 Jan 17.

20.

The reductase that catalyzes mycolic motif synthesis is required for efficient attachment of mycolic acids to arabinogalactan.

Lea-Smith DJ, Pyke JS, Tull D, McConville MJ, Coppel RL, Crellin PK.

J Biol Chem. 2007 Apr 13;282(15):11000-8. Epub 2007 Feb 17.

Items per page

Supplemental Content

Write to the Help Desk